Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: HM15136 in Congenital Hyperinsulinism (Phase 2 MAD, Open-label)
2021-000508-39Phase 2Active
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efpegerglucagon in congenital hyperinsulinism (HI), sponsored by Hanmi Pharmaceutical. Primary endpoint: Primary Objectives. Started May 2021; status: active.
02
Drugs
efpegerglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2021-000508-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000508-39.